Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Paricalcitol for Reduction of Proteinuria in Kidney Transplant Recipients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Recipients of a deceased donor kidney transplant at least 3 months after transplantation~* Urinary protein to creatinine ratio (UPCR) \> 200 mg/g (20 mg/mmol) as determined by the the mean of three second morning void urine specimens~* Subject is on stable immunosuppression for at least 3 months~* Subject is on stable doses of antihypertensive medications for at least 3 months~* Subject is not expected to begin dialysis for at least 6 months~* Estimated glomerular filtration rate \> 15 ml/min/1.73 m2~* Corrected serum calcium level \< 2.6 mmol/l~* Intact parathormone value \> 30 pg/ml~Exclusion Criteria:~* Subjects on vitamin D receptor activation therapy within 3 months prior to the first study visit~* Acute kidney injury within 3 months of the first study visit~* Subjects with poorly controlled hypertension

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Paricalcitol (Type: ACTIVE_COMPARATOR): None
- Matching placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).